<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01940081</url>
  </required_header>
  <id_info>
    <org_study_id>Cardiomyopathy study</org_study_id>
    <nct_id>NCT01940081</nct_id>
  </id_info>
  <brief_title>The Leiden Nonischemic Cardiomyopathy Study</brief_title>
  <official_title>The Leiden Nonischemic Cardiomyopathy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Sudden cardiac death, mainly caused by ventricular arrhythmias (VA), is a major&#xD;
      cause of morbidity and mortality in non-ischemic cardiomyopathy (NICM). Therapies that&#xD;
      effectively prevent VA are lacking. Improved understanding of the substrate and mechanisms of&#xD;
      VA in NICM may allow more effective, individualized and substrate-based therapies to be&#xD;
      developed. In addition, risk stratification in NICM needs to be improved so that therapies&#xD;
      can be allocated more efficiently.&#xD;
&#xD;
      Objectives: 1) To improve our understanding of the underlying pro-arrhythmic substrate and&#xD;
      electrophysiologic mechanisms of VA in NICM, and to develop individualized treatment for VA&#xD;
      based on the identified substrate. 2) To improve risk stratification for VA and sudden&#xD;
      cardiac death in NICM based on substrate characteristics. 3) to evaluate disease progression&#xD;
      in NICM.&#xD;
&#xD;
      Hypothesis: Improved understanding of the substrate and mechanisms of VA in NICM may allow&#xD;
      more effective, individualized and substrate-based therapies to be developed.&#xD;
&#xD;
      Study design: A prospective cohort study.&#xD;
&#xD;
      Study population: The study population will consist of three groups (A, B and C): NICM&#xD;
      patients with documented VA, suspected VA or intermediate to high risk for VA (according to&#xD;
      established criteria) who are not referred for cardiac surgery (group A), NICM patients with&#xD;
      documented VA, suspected VA or a high risk for VA who are referred for cardiac surgery (group&#xD;
      B) and a control group consisting of patients without NICM who are referred for cardiac&#xD;
      surgery (group C).&#xD;
&#xD;
      Evaluation: All patients will be evaluated according to current standards for patients with&#xD;
      NICM. Evaluation will include 24h-Holter, echocardiography, coronary angiogram and&#xD;
      contrast-enhanced MRI (CE-MRI). If CE-MRI is performed in another hospital, additional&#xD;
      recordings will be performed in our hospital. Additionally, blood samples (arterial, cardiac&#xD;
      venous and peripheral venous) for collagen turnover markers will be taken from all patients.&#xD;
      123-iodine metaiodobenzylguanidine (123-I MIBG) imaging, electrophysiologic study and&#xD;
      endomyocardial biopsy will be performed in group A and B. Intra-operative biopsy will be&#xD;
      performed in group B and C.&#xD;
&#xD;
      Intervention: In group B, intra-operative mapping and cryo-ablation and postoperative&#xD;
      electrophysiologic study will be performed in patients with subepicardial late enhancement on&#xD;
      MRI or induced VA suspected for an subepicardial origin.&#xD;
&#xD;
      Main study parameters/endpoints: The main study parameters are extent, location and pattern&#xD;
      of fibrosis on imaging and in biopsy specimens. The main study endpoints are inducibility of&#xD;
      VA, type of induced VA, spontaneous VA and type of spontaneous VA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inducibility of ventricular arrhythmias</measure>
    <time_frame>Baseline electrophysiological study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of induced ventricular arrhythmias</measure>
    <time_frame>Baseline electrophysiological study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Spontaneous ventricular arrhythmias</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of spontaneous ventricular arrhythmias</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital admissions for heart failure</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac mortality</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV function/dimensions/compact fibrosis deterioration as assessed by 123-I MIBG imaging and/or CE-MRI</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">148</enrollment>
  <condition>Cardiomyopathy, Dilated</condition>
  <condition>Tachycardia, Ventricular</condition>
  <condition>Ventricular Fibrillation</condition>
  <arm_group>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <description>Patients with nonischemic cardiomyopathy with:&#xD;
documented ventricular arrhythmia or&#xD;
suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or&#xD;
high risk for ventricular arrhythmia (LVEF ≤ 35%) or&#xD;
intermediate risk for ventricular arrhythmia (LVEF ≤ 50% and late enhancement on contrast-enhanced MRI)&#xD;
who are not admitted for cardiac surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Nonischemic cardiomyopathy -admitted for surgery</arm_group_label>
    <description>Patients with nonischemic cardiomyopathy with:&#xD;
documented ventricular arrhythmia or&#xD;
suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or&#xD;
high risk for ventricular arrhythmia (LVEF ≤ 35%)&#xD;
who are admitted for cardiac surgery (e.g., mitral valve annuloplasty or CorCap)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: Controls</arm_group_label>
    <description>Patients without nonischemic cardiomyopathy (controls) who are admitted for:&#xD;
Coronary artery bypass graft surgery and who do not have prior myocardial infarction&#xD;
Aortic valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transthoracic echocardiography</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy -admitted for surgery</arm_group_label>
    <arm_group_label>Group C: Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise test</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy -admitted for surgery</arm_group_label>
    <arm_group_label>Group C: Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>24-hour Holter electrocardiogram</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy -admitted for surgery</arm_group_label>
    <arm_group_label>Group C: Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Contrast-enhanced magnetic resonance imaging</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy -admitted for surgery</arm_group_label>
    <arm_group_label>Group C: Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>123-iodine metaiodobenzylguanidine imaging</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy -admitted for surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy -admitted for surgery</arm_group_label>
    <arm_group_label>Group C: Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic analysis</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy -admitted for surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Invasive electrophysiological study</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy -admitted for surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endomyocardial biopsy</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intraoperative biopsy</intervention_name>
    <arm_group_label>Group B: Nonischemic cardiomyopathy -admitted for surgery</arm_group_label>
    <arm_group_label>Group C: Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intraoperative mapping and/or ablation</intervention_name>
    <arm_group_label>Group B: Nonischemic cardiomyopathy -admitted for surgery</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Per patient:&#xD;
&#xD;
      Blood samples (40 mL) Ventricular biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with nonischemic cardiomyopathy and controls who are admitted to the hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria, group A:&#xD;
&#xD;
          -  Nonischemic cardiomyopathy&#xD;
&#xD;
          -  Documented ventricular arrhythmia, suspected ventricular arrhythmia (e.g. because of&#xD;
             out-of-hospital cardiac arrest, palpitations or syncope) or high risk for ventricular&#xD;
             arrhythmias (LVEF ≤ 35%) or intermediate risk for ventricular arrhythmias (LVEF ≤ 50%&#xD;
             and late enhancement on contrast-enhanced MRI)&#xD;
&#xD;
          -  Admission not for cardiac surgery&#xD;
&#xD;
        Inclusion criteria, group B:&#xD;
&#xD;
          -  Nonischemic cardiomyopathy&#xD;
&#xD;
          -  Documented ventricular arrhythmia or suspected ventricular arrhythmia (e.g. because of&#xD;
             out-of-hospital cardiac arrest, palpitations or syncope) or high risk for ventricular&#xD;
             arrhythmia (LVEF ≤ 35%)&#xD;
&#xD;
          -  Admission for cardiac surgery (e.g., mitral valve annuloplasty or CorCap)&#xD;
&#xD;
        Inclusion criteria, group C:&#xD;
&#xD;
        - Patients undergoing aortic valve replacement or coronary artery bypass graft surgery&#xD;
&#xD;
        Exclusion criteria, all groups:&#xD;
&#xD;
          -  Age &lt; 18 years or &gt; 80 years&#xD;
&#xD;
          -  Inadequate patient competence&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to comply with the protocol due to haemodynamic instability&#xD;
&#xD;
        Exclusion Criteria, groups A and B:&#xD;
&#xD;
        - Other cardiomyopathy (e.g., prior myocardial infarction, infiltrative cardiac disease&#xD;
        such as sarcoidosis, amyloidosis or Chagas cardiomyopathy, arrhythmogenic right ventricular&#xD;
        cardiomyopathy/dysplasia, hypertrophic cardiomyopathy, non-compaction cardiomyopathy and&#xD;
        congenital heart disease)&#xD;
&#xD;
        Exclusion criteria, group C:&#xD;
&#xD;
          -  Nonischemic cardiomyopathy&#xD;
&#xD;
          -  Prior myocardial infarction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept. of Cardiology, Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 29, 2013</study_first_submitted>
  <study_first_submitted_qc>September 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2013</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Katja Zeppenfeld</investigator_full_name>
    <investigator_title>Prof. dr.</investigator_title>
  </responsible_party>
  <keyword>Cardiomyopathy, Dilated</keyword>
  <keyword>Tachycardia, Ventricular</keyword>
  <keyword>Ventricular Fibrillation</keyword>
  <keyword>Arrhythmias, Cardiac/etiology</keyword>
  <keyword>Arrhythmias, Cardiac/physiopathology</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>3-Iodobenzylguanidine/diagnostic use</keyword>
  <keyword>Sympathetic Nervous System/radionuclide imaging</keyword>
  <keyword>Electrophysiologic Techniques, Cardiac</keyword>
  <keyword>Biopsy</keyword>
  <keyword>Genetic Testing</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Electrocardiography, Ambulatory</keyword>
  <keyword>Exercise Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

